Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Core Laboratories N.V.NYSE: CLB
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit dips below year-ago levels
Q1 FY2026 gross profit of $19.72M fell 3.3% year over year, behind the +6.9% change in trailing-twelve-month gross profit. Sequentially, it fell 21.3% from the prior quarter. Over 3 fiscal years it compounded at +6.1% a year.
Context
- Gross profit amounted to 17.9% of revenue in FY2025, up 1.0 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -3.3% toward the trailing-twelve-month pace of +6.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 94.28M USD
- Year-over-year change
- +6.7%
- 4-year CAGR
- +3.0%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 94.28M | +6.7% |
| FY2024 | 2024-12-31 | 88.37M | -6.0% |
| FY2023 | 2023-12-31 | 94.05M | +19.2% |
| FY2022 | 2022-12-31 | 78.92M | -5.9% |
| FY2021 | 2021-12-31 | 83.84M | — |
Gross Profit vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6.9% is the highest of 10, against a peer median of -43.7%.
- Gross profit amounts to 17.8% of revenue for CLB, versus a peer median of 23.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$1.31B CAD | +2.5% | +92.6% | 70.0% | |
| LTM Mar 2026 | $795.79M USD | -22.4% | -14.3% | 24.6% | |
| LTM Mar 2026 | $483.3M USD | -43.7% | +4.4% | 46.0% | |
| LTM Mar 2026 | $394.95M USD | -2.9% | -3.6% | 10.8% | |
| LTM Mar 2026 | $128.41M USD | -64.5% | -27.5% | 16.7% | |
| LTM Mar 2026 | $107.64M USD | -46.2% | -27.2% | 23.6% | |
| LTM Mar 2026 | $93.61M USD | +6.9% | +6.1% | 17.8% | |
| LTM Mar 2026 | $46.93M USD | -35.3% | -31.8% | 17.1% | |
| LTM Mar 2026 | -$16.1M USD | -127.1% | -17.3% | 4.5% | |
| LTM Mar 2026 | -$77.85M USD | -560.6% | — | 6124.7% | |
| Peer median (excluding CLB) | — | -43.7% | -15.8% | 23.6% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 470.25M | 489.74M | 509.79M | 523.85M | 526.52M |
| Cost of Revenue | 386.41M | 410.82M | 415.74M | 435.48M | 432.24M |
| Gross Profit | 83.84M | 78.92M | 94.05M | 88.37M | 94.28M |
| Gross Margin | 17.8% | 16.1% | 18.4% | 16.9% | 17.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 44.17M | 38.12M | 38.89M | 38.59M | 44.23M |
| Operating Expenses | 38.58M | 37.4M | 39.41M | 29.82M | 43.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| EBITDA | 63.78M | 58.69M | 70.42M | 73.51M | 71.12M |
| EBITDA Margin | 13.6% | 12.0% | 13.8% | 14.0% | 13.5% |
| Operating Income | 45.26M | 41.52M | 54.64M | 58.56M | 50.49M |
| Operating Margin | 9.6% | 8.5% | 10.7% | 11.2% | 9.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.15M | 11.57M | 13.43M | 12.37M | 10.57M |
| Other Income / Expenses | (9.15M) | (11.57M) | (13.43M) | (12.37M) | (4.59M) |
| Income Before Tax | 36.11M | 29.95M | 41.21M | 46.19M | 45.9M |
| Pre-Tax Margin | 7.7% | 6.1% | 8.1% | 8.8% | 8.7% |
| Income Tax Expense | 15.89M | 10.3M | 4.19M | 14.03M | 15.51M |
| Net Income | 19.73M | 19.45M | 36.68M | 31.4M | 29.67M |
| Net Margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
| EPS (Basic) | 0.43 | 0.42 | 0.79 | 0.67 | 0.68 |
| EPS (Diluted) | 0.42 | 0.42 | 0.77 | 0.66 | 0.68 |
| Weighted Avg Shares | 46.01M | 46.33M | 46.68M | 46.9M | 46.5M |
| Weighted Avg Shares (Diluted) | 46.69M | 46.81M | 47.52M | 47.69M | 46.5M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.